Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

Research output: Contribution to journalArticle

Authors

  • MS Braun
  • F Adab
  • C Bradley
  • K McAdam
  • G Thomas
  • NJ Wadd
  • R Philips
  • C Twelves
  • J Bozzino
  • C MacMillan
  • MP Saunders
  • R Counsell
  • H Anderson
  • A McDonald
  • J Stewart
  • A Robinson
  • S Davies
  • FJ Richards
  • MT Seymour

Colleges, School and Institutes

Abstract

We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.

Details

Original languageEnglish
Pages (from-to)1155-1158
Number of pages4
JournalBritish Journal of Cancer
Volume89
Issue number7
Publication statusPublished - 6 Oct 2003

Sustainable Development Goals